Oncology and Hematology

Episodes 49-57 of 57

• 

  RestartResume

  Current Unmet Needs in the Field of Unresectable HCC

  RestartResume

  Current Unmet Needs in the Field of Unresectable HCC

  MinuteCE®

  Current Unmet Needs in the Field of Unresectable HCC

  1.00 program credit

  • 

    

    Ghassan K. Abou-Alfa, MD

  • 

    

    Aiwu Ruth He, MD, PhD

  1.00 program credit

• 

  RestartResume

  Enhancing Outcomes in Unresectable HCC Through Integrated Multidisciplinary Care Models

  RestartResume

  Enhancing Outcomes in Unresectable HCC Through Integrated Multidisciplinary Care Models

  MinuteCE®

  Enhancing Outcomes in Unresectable HCC Through Integrated Multidisciplinary Care Models

  1.00 program credit

  • 

    

    Ghassan K. Abou-Alfa, MD

  • 

    

    Aiwu Ruth He, MD, PhD

  1.00 program credit

• 

  RestartResume

  Pivotal Data Supporting First-Line Atezolizumab/Bevacizumab in Unresectable HCC

  RestartResume

  Pivotal Data Supporting First-Line Atezolizumab/Bevacizumab in Unresectable HCC

  MinuteCE®

  Pivotal Data Supporting First-Line Atezolizumab/Bevacizumab in Unresectable HCC

  1.00 program credit

  • 

    

    Aiwu Ruth He, MD, PhD

  1.00 program credit

• 

  RestartResume

  Emerging First-Line ICI Combination Regimens in Patients With Unresectable HCC

  RestartResume

  Emerging First-Line ICI Combination Regimens in Patients With Unresectable HCC

  MinuteCE®

  Emerging First-Line ICI Combination Regimens in Patients With Unresectable HCC

  1.00 program credit

  • 

    

    Ghassan K. Abou-Alfa, MD

  1.00 program credit

• 

  RestartResume

  Case Consult: Treatment Options for an Unresectable HCC Patient Who Has Esophageal Varices

  RestartResume

  Case Consult: Treatment Options for an Unresectable HCC Patient Who Has Esophageal Varices

  MinuteCE®

  Case Consult: Treatment Options for an Unresectable HCC Patient Who Has Esophageal Varices

  1.00 program credit

  • 

    

    Aiwu Ruth He, MD, PhD

  1.00 program credit

• 

  RestartResume

  Selecting the Optimal ICI Partner for First-Line Treatment of Unresectable HCC: CTLA-4 vs VEGFInhibitors

  RestartResume

  Selecting the Optimal ICI Partner for First-Line Treatment of Unresectable HCC: CTLA-4 vs VEGFInhibitors

  MinuteCE®

  Selecting the Optimal ICI Partner for First-Line Treatment of Unresectable HCC: CTLA-4 vs VEGFInhibitors

  1.00 program credit

  • 

    

    Ghassan K. Abou-Alfa, MD

  • 

    

    Aiwu Ruth He, MD, PhD

  1.00 program credit

• 

  RestartResume

  Pivotal Data Supporting First-Line Durvalumab/Tremelimumab in Unresectable HCC

  RestartResume

  Pivotal Data Supporting First-Line Durvalumab/Tremelimumab in Unresectable HCC

  MinuteCE®

  Pivotal Data Supporting First-Line Durvalumab/Tremelimumab in Unresectable HCC

  1.00 program credit

  • 

    

    Ghassan K. Abou-Alfa, MD

  1.00 program credit

• 

  RestartResume

  Empowering Treatment Choice: The Essential Role of Shared Decision-Making in Unresectable HCC

  RestartResume

  Empowering Treatment Choice: The Essential Role of Shared Decision-Making in Unresectable HCC

  MinuteCE®

  Empowering Treatment Choice: The Essential Role of Shared Decision-Making in Unresectable HCC

  1.00 program credit

  • 

    

    Ghassan K. Abou-Alfa, MD

  • 

    

    Aiwu Ruth He, MD, PhD

  1.00 program credit

• 

  RestartResume

  Managing Adverse Events Associated With ICI Combinations in Patients With Unresectable HCC

  RestartResume

  Managing Adverse Events Associated With ICI Combinations in Patients With Unresectable HCC

  MinuteCE®

  Managing Adverse Events Associated With ICI Combinations in Patients With Unresectable HCC

  1.00 program credit

  • 

    

    Aiwu Ruth He, MD, PhD

  1.00 program credit